Capricor Therapeutics Inc Stock Nasdaq
Stocks
US14070B1017
Biotechnology & Medical Research
| Market Cap | 471M 421M 392M 356M 671M 45.61B 677M 4.71B 1.84B 23.18B 1.77B 1.73B 74.54B | P/E 2026 * |
-4.42x | P/E 2027 * | -5.44x |
|---|---|---|---|---|---|
| Enterprise Value | 471M 421M 392M 356M 671M 45.61B 677M 4.71B 1.84B 23.18B 1.77B 1.73B 74.54B | EV / Sales 2026 * |
8.46x | EV / Sales 2027 * | 8.33x |
| Free-Float |
90.56% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Capricor Therapeutics Inc
| 1 day | +10.01% |
| Manager | Title | Age | Since |
|---|---|---|---|
Linda Marbán
CEO | Chief Executive Officer | 62 | 20/11/2013 |
Anthony Bergmann
DFI | Director of Finance/CFO | 40 | 01/01/2018 |
Michael Binks
CTO | Chief Tech/Sci/R&D Officer | - | 13/05/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Frank Litvack
CHM | Chairman | 70 | 01/11/2013 |
David Musket
BRD | Director/Board Member | 68 | 20/11/2013 |
George Dunbar
BRD | Director/Board Member | 79 | 20/11/2013 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +10.01% | -11.80% | - | - | 471M | |
| -3.19% | -3.19% | +44.60% | +87.98% | 74.68B | |
| -15.86% | -16.67% | +3.92% | +50.90% | 58.7B | |
| -2.39% | -2.05% | +4.29% | +31.33% | 48.36B | |
| -6.35% | -8.35% | +303.95% | +651.28% | 43.05B | |
| +0.30% | -3.71% | +28.89% | +30.33% | 42.48B | |
| -3.82% | -4.32% | +2.49% | +101.36% | 41.39B | |
| -2.13% | +1.07% | +7.51% | +50.31% | 31.29B | |
| -3.35% | -6.35% | -13.20% | -17.22% | 23.93B | |
| -1.24% | -11.97% | -38.10% | +311.13% | 22.22B | |
| Average | -2.79% | -2.63% | +38.26% | +144.16% | 42.9B | |
| Weighted average by Cap. | -4.83% | -1.88% | +44.70% | +136.42% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 55.69M 49.73M 46.39M 42.14M 79.3M 5.39B 80.08M 557M 218M 2.74B 209M 205M 8.81B | 56.54M 50.49M 47.1M 42.79M 80.51M 5.48B 81.3M 565M 221M 2.78B 212M 208M 8.95B |
| Net income | -132M -118M -110M -99.88M -188M -12.78B -190M -1.32B -516M -6.5B -496M -485M -20.89B | -89.51M -79.93M -74.57M -67.74M -127M -8.67B -129M -895M -350M -4.41B -336M -329M -14.17B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
